Gastroenterology
Volume 135, Issue 5 , Pages 1450-1451 , November 2008

Portal Hypertension in Primary Biliary Cirrhosis: A Potentially Reversible Harbinger of Demise

  • Marlyn J. Mayo

      Affiliations

    • Corresponding Author InformationAddress requests for reprints to: Marlyn J. Mayo, MD, Associate Professor of Internal Medicine, Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9151. fax: 214-648-8274

References 

  1. Huet PM, Vincent C, Deslaurier J, et al. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. Gastroenterology. 2008;153:1552–1560
  2. Zeeagen R, Stansfeld AG, Dawson AM, et al. Bleeding oesophageal varices as the presenting feature in primary biliary cirrhosis. Lancet. 1969;2:9–13
  3. Lebrec D, Sicot C, Degott C, et al. Portal hypertension and primary biliary cirrhosis. Digestion. 1976;14:220–226
  4. Kew MC, Varma RR, Dos Santos HA, et al. Portal hypertension in primary biliary cirrhosis. Gut. 1971;12:830–834
  5. Garrido MC, Hubscher SG. Accuracy of staging in primary biliary cirrhosis. J Clin Pathol. 1996;49:556–559
  6. Colina F, Pinedo F, Solis JA, et al. Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis. Gastroenterology. 1992;102:1319–1324
  7. Levy K, Zein CO, Gomez J, et al. Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2007;5:803–808
  8. Bressler B, Pinto R, El-Ashry D, Heathcote J. Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection?. Gut. 2005;54:407–410
  9. Lindor KD, Jorgensen RA, Therneau TM, et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc. 1997;72:1137–1140
  10. Combes B, Carithers RL, Maddrey WC, et al. A randomized double-blind placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1995;22:759–766
  11. Oka H, Toda G, Ikeda Y, et al. A multi-center double blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterologia Japonica. 1990;25:774–780
  12. Gong Y, Huang ZB, Christensen E, et al. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database of Systematic Reviews. 2008;1:CD000551;DOI: 10.1002/14651858.CD000551.pub2
  13. Pares A, Caballeria L, Rodes J, et al. Long term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. J Hepatol. 2000;32:561–566
  14. Vuoristo M, Farkkila M, Gylling H, et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology. 1995;108:1470–1478
  15. Lindor KD, Dickson Er, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 1994;106:1284–1290
  16. Poupon RE, Balkau B, Eschwege E, et al. The UDCA-PBC Study Group A multi-center, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med. 1991;324:1548–1554

 The author discloses no conflicts.

PII: S0016-5085(08)01771-X

doi: 10.1053/j.gastro.2008.09.041

Gastroenterology
Volume 135, Issue 5 , Pages 1450-1451 , November 2008

Article Tools